Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Duvelisib · 1 trial · 2 indications
Will estimate fold-change increase in CD27/CD28 double positive T cells following in vivo exposure to duvelisib using multiparametric flow cytometry.
| Arm | Type | Description |
|---|---|---|
| Treatment (duvelisib) | EXPERIMENTAL | Patients receive duvelisib PO BID for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion. |
| Name | Type | Description |
|---|---|---|
| Duvelisib | DRUG | Given PO |
| Tisagenlecleucel | BIOLOGICAL | Given via infusion |
Inclusion Criteria: * Patients must have a biopsy proven diagnosis of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) * Eastern Cooperative Oncology Group (ECOG) \< 2 * Serum creatinine (Cr) \< 2.0 mg/dL * Alanine aminotransferase (AST)/aspartate aminotransferase (ALT) \< 2 x upper limit ...
Duvelisib is being studied for the treatment of recurrent and refractory Diffuse Large B-Cell Lymphoma. It is an investigational small molecule in Phase 1 clinical development. The drug is intended to enhance immune profiles of T cells in patients with this condition.
Duvelisib is a small molecule designed to enhance the immune profiles of T cells in patients with recurrent or refractory Diffuse Large B-Cell Lymphoma. The treatment aims to modify T cell function to improve the body's immune response against the cancer.
Duvelisib is being developed by Novartis AG, a company traded on the stock exchange under the ticker NVS. The drug is currently in Phase 1 clinical development for recurrent Diffuse Large B-Cell Lymphoma.
Duvelisib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in an early-phase clinical trial for recurrent and refractory Diffuse Large B-Cell Lymphoma.
Duvelisib is being studied in clinical trial NCT04890236, titled "Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study." This early Phase 1 trial has been completed and enrolled 4 participants in the United States.
Duvelisib is a distinct investigational drug being developed by Novartis AG. It is a small molecule intended for use in recurrent Diffuse Large B-Cell Lymphoma. No alternative names for this drug have been established in the clinical development program.